Department Microbiology and Immunology, Rega Institute for Medical Research, Clinical and Epidemiological Virology, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium.
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1159-78. doi: 10.1586/14787210.2013.844649.
Up until 10 years ago, basic and clinical HIV-1 research was mainly performed on HIV-1 subtype B that predominated in resource-rich settings. Over the past decade, HIV-1 care and therapy has been scaled up substantially in Latin America, Africa and Asia. These regions are largely dominated by non-B subtype infections, and especially the African continent is affected by the HIV pandemic. Insight on the potency of antiviral drugs and regimens as well as on the emergence of drug resistance in non-B subtypes was lacking triggering research in this field, also partly driven by the introduction and spreading of HIV-1 non-B subtypes in Europe. The scope of this article was to review and discuss the state-of-the-art on the impact of HIV-1 genetic variation on the in vitro activity of antiviral drugs and in vivo response to antiviral therapy; as well as on the in vitro and in vivo emergence of drug resistance.
直到 10 年前，HIV-1 的基础和临床研究主要针对在资源丰富的环境中占主导地位的 HIV-1 亚型 B 进行。在过去的十年中，拉丁美洲、非洲和亚洲的 HIV-1 护理和治疗得到了大规模的扩展。这些地区主要受到非 B 亚型感染的影响，特别是非洲大陆受到 HIV 大流行的影响。在非 B 亚型中缺乏对抗病毒药物和方案的效力以及耐药性出现的了解，这促使该领域开展了研究，部分原因是 HIV-1 非 B 亚型在欧洲的引入和传播。本文的目的是回顾和讨论 HIV-1 遗传变异对体外抗病毒药物活性和体内抗病毒治疗反应的影响；以及体外和体内耐药性的出现。
